Skip to main navigation Skip to search Skip to main content

Sotagliflozin in patients with diabetes and chronic kidney disease

  • Deepak L. Bhatt*
  • , Michael Szarek
  • , Bertram Pitt
  • , Christopher P. Cannon
  • , Lawrence A. Leiter
  • , Darren K. McGuire
  • , Julia B. Lewis
  • , Matthew C. Riddle
  • , Silvio E. Inzucchi
  • , Mikhail N. Kosiborod
  • , David Z.I. Cherney
  • , Jamie P. Dwyer
  • , Benjamin M. Scirica
  • , Clifford J. Bailey
  • , Rafael Díaz
  • , Kausik K. Ray
  • , Jacob A. Udell
  • , Renato D. Lopes
  • , Pablo Lapuerta
  • , P. Gabriel Steg
  • *Corresponding author for this work
  • Harvard University
  • Colorado Prevention Center
  • State University of New York Downstate
  • University of Michigan
  • Li Ka Shing Knowledge Institute
  • University of Texas at Dallas
  • Vanderbilt University Medical Center
  • Oregon Health and Science University
  • Yale University
  • University of Missouri-Kansas City
  • University Health Network University of Toronto
  • Instituto Cardiovascular de Rosario
  • Royal Brompton Hospital
  • University Health Network
  • Duke Clinical Research Institute
  • Lexicon Pharmaceuticals
  • Institut National de la Santé et de la Recherche Médicale

Research output: Contribution to journalArticlepeer-review

1073   Link opens in a new tab Citations (SciVal)
25 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Sotagliflozin in patients with diabetes and chronic kidney disease'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases